oncolytic Newcastle disease virus strain PV701

PV701 is a naturally attenuated, non-recombinant, replication-competent oncolytic strain of the Newcastle disease virus (NDV) developed as an intravenous cancer therapy. It selectively infects and lyses human tumor cells due to tumor-specific defects in the interferon-mediated antiviral response while sparing normal cells. The mechanism of action involves direct infection and lysis (bursting) of cancer cells by the virus. Preclinical studies demonstrated broad-spectrum antitumor activity both *in vitro* and *in vivo*. Clinical trials have shown that desensitization strategies and slow infusion rates can improve tolerability and allow higher dosing. Tumor responses have been observed in phase 1 studies for various advanced solid tumors[1][2][3][4][5][6][7].

Other names

oncolytic Newcastle disease virus strain PV701oncolytic Newcastle disease virusNewcastle disease virus strain PV701